Alert detail
LCD L39709: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — WPS
What changed
WPS covers GEP tests for castration-resistant/metastatic prostate CA
Who’s affected: Oncology billing teams · Effective: September 22, 2024
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.